Creative Medical Technology Holdings (CELZ) Cash from Investing Activities (2016 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Cash from Investing Activities of -$175000.0 for Q1 2026, down 246.53% quarter-over-quarter from -$50500.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Cash from Investing Activities (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Cash from Investing Activities for 9 consecutive years, with -$175000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$175000.0; the TTM figure through Mar 2026 stood at -$225500.0 (down 12.75% YoY), while the FY2025 annual figure was -$50500.0, down 100.8% from the prior year.
- Cash from Investing Activities fell to -$175000.0 in Q1 2026 per CELZ's latest filing, from -$50500.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $6.5 million in Q1 2024 and bottomed at -$5.1 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$53874.1 across 5 years, with a median of -$112750.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 2628.66% — and 2023, when it jumped 140.11%.
- Creative Medical Technology Holdings' Cash from Investing Activities stood at -$5.1 million in 2022, then surged by 118.47% to $933914.0 in 2023, then sank by 121.42% to -$200000.0 in 2024, then soared by 74.75% to -$50500.0 in 2025, then slumped by 246.53% to -$175000.0 in 2026.
- Business Quant data shows CELZ's Cash from Investing Activities at -$175000.0 in Q1 2026, -$50500.0 in Q4 2025, and -$200000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,000.00 |
| Mar 31, 2026 | -175,000.00 |
| Dec 31, 2025 | -50,500.00 |
| Dec 31, 2025 | -50,500.00 |
| Sep 30, 2024 | -200,000.00 |
| Sep 30, 2024 | -200,000.00 |
| Mar 31, 2024 | 6.52 Mn |
| Mar 31, 2024 | 6.52 Mn |
| Dec 31, 2023 | 933,914.00 |
| Dec 31, 2023 | 933,914.00 |
| Sep 30, 2023 | 2.01 Mn |
| Sep 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | -4.54 Mn |
| Jun 30, 2023 | -4.54 Mn |
| Mar 31, 2023 | 5.04 Mn |
| Mar 31, 2023 | 5.04 Mn |
| Dec 31, 2022 | -5.06 Mn |
| Dec 31, 2022 | -5.06 Mn |
| Sep 30, 2022 | -5.02 Mn |
| Sep 30, 2022 | -5.02 Mn |